Financing ·
Evogene Ltd. increased its at-the-market offering amount from $2,926,500 to $3,288,113 under its Sales Agreement with…
EVGNEvogene Ltd.
Evogene Ltd. increased its at-the-market offering amount from $2,926,500 to $3,288,113 under its Sales Agreement with A.G.P./Alliance Global Partners. The company also updated its risk factors to include risks associated with shareholder activism and potential proxy contests, following a demand by certain shareholders to call an extraordinary general meeting to replace most of the Board of Directors. Evogene Ltd. is a biotechnology company focused on on-demand plant-based solutions.